Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
DOCS Boosts Client Retention via Workflow Integration and AI Tools
Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
Over the past month, Doximity's DOCS shares have lost approximately 4.4% despite the company reporting solid fourth-quarter fiscal 2025 results with $138.3 million in revenues and a 50% adjusted EBITDA margin. For fiscal 2025, revenues totaled $570.4 million, up 20% year over year, with adjusted EBITDA rising 36% to $313.8 million and margin expanding to 55%.
Dr Martens surges 23% as investors lace up for recovery story
Shares in Dr Martens PLC (LSE:DOCS) jumped 23% on Thursday after the bootmaker delivered a better-than-expected full-year update and signalled a shift towards stabilisation and future growth, giving investors reason to believe the worst may be behind it. The British brand, known for its chunky leather boots, reported adjusted pre-tax profits of £34.1 million for the year to March, around £2 million ahead of consensus and squarely in line with Peel Hunt's forecast.
Dr Martens marketing 'reset' saw annual revenue and profit retreat, eyes return to growth this year
Dr Martens PLC (LSE:DOCS) reported a 10% drop in group revenue to £787.6 million for the year ended 30 March 2025, amidst a marketing 'reset'. Adjusted profit before tax fell to £34.1 million from £97.2 million, the boot brand said in the results statement.
The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks
His concentrated portfolio strategy, focusing on high-quality, long-term holdings, reflects a disciplined, tech-heavy investment approach.
Doximity Rides on Telehealth Demand: Will This Drive Sales Further?
DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs.
Dr Martens interims a first test for new CEO after shares stumble to all-time low
Dr Martens PLC (LSE:DOCS) shares stumbled to a new all-time low below 50p last month after the US tariff announcement, but have been tiptoeing higher in the run-up to interim results due next Thursday, 5 June. Back in January, the boot-maker flagged "good progress" in its turnaround after revenue ticked up 3% on a constant currency basis during the third quarter, aided by stronger American and Asia Pacific sales, offsetting a decline in Europe due to strong promotional activity from rivals in December.
Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up
DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.
Doximity, Inc. (DOCS) Q4 2025 Earnings Call Transcript
Doximity, Inc. (NYSE:DOCS ) Q4 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Perry Gold - Head of IR Jeff Tangney - Co-Founder and CEO Anna Bryson - CFO Nate Gross - Co-Founder and CSO Conference Call Participants Brian Peterson - Raymond James Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Ryan MacDonald - Needham Jared Haase - William Blair Allen Lutz - Bank of America Scott Schoenhaus - KeyBanc Ann Samuel - JPMorgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Steven Veliquette - Mizuho Securities Jeff Garro - Stephens David Roman - Goldman Sachs Jailendra Singh - Truist Craig Hettenbach - Morgan Stanley Operator Good day, everyone, and welcome to the Doximity Q4 2025 Earnings Call. At this time, I will hand the call over to Perry Gold, Head of IR.
Doximity (DOCS) Surpasses Q4 Earnings and Revenue Estimates
Doximity (DOCS) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.25 per share a year ago.
Doximity Stock Drops 20% After Outlook Disappoints
Shares of Doximity plummeted late Thursday after the telehealth software company dished out a disappointing outlook.
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
